⚖️ Problem 💔 Reason 🔬 Remedy 📋 The Playbook 🥼 The Whitecoat Rebellion
🎙️ Voices 🏛️ Congress 📋 Legislation ⚠️ S.3822+ 🔧 Framework ⚔️ States 📰 Media
Rep. Dunn Rep. Murphy Sen. Hawley Sen. Warren Rep. AOC Fmr. Rep. Wenstrup Rep. Ryan Rep. Mackenzie Sen. Grassley Rep. Jayapal
Remedy Room Congressional Voices Rep. Alexandria Ocasio-Cortez
Rep. Alexandria Ocasio-Cortez

Congressional Voices — 5 of 5 · Democrat · New York NY-14

Rep. Alexandria Ocasio-Cortez (D-NY)

U.S. House · House Health Subcommittee Hearing · January 22, 2026 · CVS CEO David Joyner on the Record

Democrat CVS CEO on the Record Glass-Steagall for Healthcare Jan 22 Convergence

What She Did That No One Else Did

Other members described the problem. AOC put the person responsible for it on record, under questioning, defending it. CVS CEO David Joyner had to either admit the captive strategy harms patients or defend it as a consumer benefit — and the FTC's own findings on medication markups made that defense actively damaging. She chose the right question in the right room with the right CEO present.

Tell Them AbilityForge Sent You

This member is on record supporting healthcare accountability reform. Contact them to express your appreciation and urge them to push S.3822 forward. Every constituent call counts — let them know the people they serve are watching.

Democrat House of Representatives New York — NY-14 House Health Subcommittee Hearing — Jan 22, 2026

At the January 22, 2026 House Health Subcommittee hearing — the same hearing where Rep. Murphy disclosed his eight-attempt prior authorization experience — Rep. Ocasio-Cortez put CVS Health CEO David Joyner on the record about vertical integration. In rapid succession, she confirmed on the record that CVS Health simultaneously owns Aetna (insurance), CVS Pharmacies, and CVS Caremark — a pharmacy benefit manager processing nearly 30% of all U.S. prescriptions annually.

She then named what the FTC had documented: that healthcare conglomerates structured this way charge more — citing thousand-percent markups on cancer and HIV medications — while former CVS CEO Karen Lynch had acknowledged internally that their "captive strategy" would "show up on their financial results," without any corresponding improvement in patient costs or health outcomes.

The Exchange · January 22, 2026

AOC

"Whether you're a blue blooded capitalist or a card carrying democratic socialist, I think corporate monopolies are a problem. And this vertical integration is destroying people's ability to access care."

AOC

[On CVS's "captive strategy" benefiting patients] "Yeah. I think it works very well for CVS."

— Rep. Alexandria Ocasio-Cortez (D-NY), House Health Subcommittee Hearing, January 22, 2026

Rep. Ocasio-Cortez has not reviewed or endorsed S.3822 specifically. This statement represents independent convergence — a progressive Democrat arriving at the same structural monopoly diagnosis as Sen. Warren, Sen. Hawley, and Rep. Murphy, from her own questioning of CVS's CEO under oath. She called explicitly for a "Glass-Steagall for Health Care" — the same structural separation S.3822 codifies.

Read the Official Press Release →
Watch on YouTube — AOC vs CVS Hearing

The "Kate" Example

To illustrate closed-loop capture, AOC described a fictional patient named Kate — holding an Aetna plan, filling prescriptions at CVS Pharmacy, connected to an Oak Street Health clinic. Every touchpoint in Kate's care funnels revenue to the same parent company. Kate never consented to that arrangement. She just got sick. The fiction makes the structure visible in a way a regulatory filing cannot.

The Jan 22 Convergence

The January 22 hearing produced two of the most widely shared congressional moments on this issue simultaneously: Rep. Murphy's eight-attempt disclosure and AOC's CVS exchange. Both went viral. Both arrived at the same structural conclusion from opposite ends of the political spectrum — on the same day, in the same building. The argument has escaped partisan framing. See Rep. Murphy's page →

Why this matters for S.3822 — Break Up Big Medicine:

AOC's exchange did something the bill text alone cannot do: it put a CVS CEO on record, under questioning, acknowledging the ownership structure while defending it as a consumer benefit — a defense that the FTC's own findings on medication markups directly contradict. Her call for a "Glass-Steagall for Health Care" is precisely the structural logic S.3822 enacts. When a progressive Democrat, a conservative Republican (Hawley), and two physician-congressmen (Murphy, Dunn) are all naming the same mechanism in the same session of Congress, the structural case has achieved rare cross-spectrum consensus. S.3822 is the legislation that answers all of them.

Other Members in This Series